Investors

2016 Annual Letter to Shareholders (click to open)

We are committed to providing our shareholders with accessible, complete information about our company. Within this section of the website, you will find comprehensive stock information, corporate data and progress reports.

Investment Highlights

  • Recent entry into high-profile Zika vaccine space with multiple collaborators
  • Second generation Hemorrhagic Fever vaccine (Ebola, Marburg, Lassa) offering broad coverage and distinct advantages vs existing vaccines
  • Multiple targets in the Cancer Immunotherapy space
  • Most clinically advanced vaccine candidate for prevention of HIV infection in the developed world (HIV clade B – US, Western Europe)
  • Novel vaccine technology developed at Emory University, NIH and CDC
  • Proven vaccine protection in HIV and Ebola animal models
  • Demonstrated human safety of MVA-VLP vaccine platform in hundreds of subjects to date
  • Equity capital leveraged with significant non-dilutive NIH support for clinical trials and research grants (>$50 million to date)
  • Strong global patent position with additional manufacturing technical know-how barriers to entry